RadNet, Inc. (NASDAQ:RDNT) is Emerald Advisers LLC's 8th Largest Position

Emerald Advisers LLC lessened its stake in shares of RadNet, Inc. (NASDAQ:RDNT - Free Report) by 1.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 657,189 shares of the medical research company's stock after selling 12,061 shares during the period. RadNet makes up approximately 1.8% of Emerald Advisers LLC's holdings, making the stock its 8th largest holding. Emerald Advisers LLC owned approximately 0.89% of RadNet worth $45,898,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. HighTower Advisors LLC boosted its position in shares of RadNet by 1.8% during the third quarter. HighTower Advisors LLC now owns 7,861 shares of the medical research company's stock valued at $545,000 after buying an additional 136 shares during the period. Highland Capital Management LLC boosted its holdings in RadNet by 6.5% during the 4th quarter. Highland Capital Management LLC now owns 3,307 shares of the medical research company's stock valued at $231,000 after acquiring an additional 202 shares during the period. Virtue Capital Management LLC boosted its holdings in RadNet by 1.4% during the 3rd quarter. Virtue Capital Management LLC now owns 19,389 shares of the medical research company's stock valued at $1,345,000 after acquiring an additional 264 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd grew its position in RadNet by 4.3% in the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 7,389 shares of the medical research company's stock valued at $516,000 after acquiring an additional 302 shares during the last quarter. Finally, Fifth Third Bancorp increased its stake in RadNet by 84.3% in the fourth quarter. Fifth Third Bancorp now owns 667 shares of the medical research company's stock worth $47,000 after purchasing an additional 305 shares during the period. 77.90% of the stock is currently owned by institutional investors.

Remove Ads

RadNet Stock Down 0.1 %

NASDAQ:RDNT traded down $0.05 during trading hours on Thursday, reaching $50.67. The company's stock had a trading volume of 823,399 shares, compared to its average volume of 615,846. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.16 and a current ratio of 2.16. The company has a market capitalization of $3.75 billion, a P/E ratio of -723.75 and a beta of 1.85. The stock has a 50 day moving average price of $57.76 and a two-hundred day moving average price of $67.13. RadNet, Inc. has a 12 month low of $45.82 and a 12 month high of $93.65.

RadNet (NASDAQ:RDNT - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The medical research company reported $0.22 earnings per share for the quarter, topping analysts' consensus estimates of $0.21 by $0.01. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. The firm had revenue of $477.10 million during the quarter, compared to analysts' expectations of $459.42 million. Equities analysts predict that RadNet, Inc. will post 0.56 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RDNT has been the topic of a number of research analyst reports. Jefferies Financial Group cut their price target on shares of RadNet from $100.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday, January 15th. Truist Financial restated a "buy" rating and issued a $88.00 target price (down from $94.00) on shares of RadNet in a research note on Wednesday, January 22nd. Raymond James raised shares of RadNet from an "outperform" rating to a "strong-buy" rating and decreased their price target for the company from $85.00 to $65.00 in a research note on Wednesday, March 5th. Barclays lowered their price target on RadNet from $74.00 to $60.00 and set an "overweight" rating for the company in a report on Monday. Finally, StockNews.com upgraded RadNet to a "sell" rating in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $73.25.

Insider Activity

In other RadNet news, COO Norman R. Hames sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $49.79, for a total value of $248,950.00. Following the completion of the sale, the chief operating officer now directly owns 261,959 shares in the company, valued at $13,042,938.61. This trade represents a 1.87 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David L. Swartz sold 25,000 shares of the company's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $50.84, for a total value of $1,271,000.00. Following the transaction, the director now directly owns 174,067 shares in the company, valued at approximately $8,849,566.28. The trade was a 12.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,000 shares of company stock worth $1,926,730. Corporate insiders own 5.12% of the company's stock.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.